Dishman Carbogen Amcis stock jumps 11% after receiving drug manufacturing license from NMPA for Shanghai, ChinaDishman Carbogen Amcis stock jumps 11% after receiving drug manufacturing license from NMPA for Shanghai, China

Introduction:

Leading pharmaceutical company’s wholly owned subsidiary has secured a Drug Manufacturing License from China’s National Medical Products Administration for its Shanghai facility, marking a significant step in global expansion and regulatory compliance.

Also Read: Pharma stock: Biocon receives USFDA approval for antibody used in curing different types of cancer

Share price movement of Dishman Carbogen Amcis:

On April 11, 2025, Dishman Carbogen Amcis Ltd opened at ₹195.00, up 4.00% from its previous close of ₹187.50. The stock touched a high of ₹207.00 (10.40%) and a low of ₹195.00. By 10:54 AM, it traded at ₹199.90, rising 6.61%, with a market cap of ₹3,134.09 crore.

Dishman Carbogen Amcis Subsidiary Receives Drug Manufacturing License in China:

Dishman Carbogen Amcis Ltd. announced that its wholly owned subsidiary, Carbogen Amcis (Shanghai) Co. Ltd., has received a Drug Manufacturing License from China’s National Medical Products Administration (NMPA) for its Shanghai site.

This regulatory approval marks a key milestone in expanding the company’s global pharmaceutical manufacturing capabilities. The license enables the subsidiary to manufacture drugs in China, strengthening Dishman Carbogen Amcis’ presence in the Asian market and supporting its long-term growth plans.

Ace investor holding in Dishman Carbogen Amcis:

Mukul Mahavir Agrawal

Mukul Mahavir Agrawal holds a 5.50% stake in Dishman Carbogen Amcis Ltd, with 8,617,000 shares worth ₹169.5 crore, highlighting his strong presence in the pharma space.

Stock performance of Dishman Carbogen Amcis for Period of 1 week, 6 months, and 1 year:

Dishman Carbogen Amcis Ltd delivered a -9.81% return over the past week. It gained 2.78% in the past six months but declined 22.4% over the past year.

Also Read: Stocks to Watch: 6 Stocks to watch for tomorrow’s market

Shareholding pattern of Dishman Carbogen Amcis:

Particulars	Dec 2024	Sep 2024	Jun 2024
Promoter	59.30%	59.30%	59.30%
FII	8.80%	8.20%	8.10%
DII	1%	1.20%	2%
Public	30.50%	31.30%	31.20%

About Dishman Carbogen Amcis:

Dishman Carbogen Amcis Ltd (NSE: DCAL) is a global CRAMS player, producing specialty chemicals, vitamins, and disinfectants, with operations across Switzerland, UK, Europe, China, and other international markets.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.